Medicus Pharma Ltd (MDCX)

NASD · Healthcare · Drug Manufacturers - General · Canada

Medicus Pharma Ltd is a micro cap company (market value under $300 million) in the Drug Manufacturers - General industry.

Medicus Pharma Ltd is a clinical stage biotech company developing novel therapeutic assets across multiple countries. Through subsidiaries SkinJect and Antev, it develops a doxorubicin-containing microneedle array for non-melanoma skin cancers and a hormone antagonist for prostate cancer and urinary retention conditions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Medicus Pharma Ltd stock.

Our verdict on MDCX

Not valued: We cannot value this company yet.

Browse

• Stocks in Canada
• Healthcare stocks in Canada

Peers in Drug Manufacturers - General

• Lilly(Eli) & Co (LLY)
• Johnson & Johnson (JNJ)
• Abbvie Inc (ABBV)
• Merck & Co Inc (MRK)
• Novartis AG ADR (NVS)
• Astrazeneca plc (AZN)
• AMGEN Inc (AMGN)
• Gilead Sciences Inc (GILD)

All 21 Drug Manufacturers - General stocks

Cheaper than MDCX in Drug Manufacturers - General

• Organon & Co (OGN): undervalued, 50% margin of safety
• Bristol-Myers Squibb Co (BMY): undervalued, 50% margin of safety
• Novo Nordisk ADR (NVO): undervalued, 49% margin of safety
• Pfizer Inc (PFE): undervalued, 41% margin of safety
• GSK Plc ADR (GSK): undervalued, 33% margin of safety
• Astrazeneca plc (AZN): slightly overvalued, -14% margin of safety

9 more in this industry show a wider margin of safety.

Is MDCX undervalued or overvalued?

We do not publish a verdict on MDCX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of MDCX?

We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.